UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Form 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of
earliest event reported) February 8, 2008
Bentley Pharmaceuticals, Inc.
(Exact name of Registrant as specified in its charter)
| |
|
|
|
|
| Delaware
|
|
1-10581
|
|
59-1513162 |
(State or other jurisdiction
of incorporation)
|
|
(Commission File No.)
|
|
(I.R.S. Employer
Identification Number) |
| |
|
|
|
|
Bentley Park
2 Holland Way
Exeter, New Hampshire |
|
|
|
03833 |
(Address of principal
executive office) |
|
|
|
(Zip Code) |
Registrant’s telephone number, including area code (603) 658-6100
No change since last report
(Former name or former address if
changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Securities Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
TABLE OF CONTENTS
ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.
On February 8, 2008, we entered into a letter amendment (the “Amendment”) with Yungtai Hsu
effective December 31, 2007 that clarified the basis on which royalties are paid under the Asset
Purchase Agreement with Yungtai Hsu, dated February 1, 1999, effective as of December 31, 1998.
The Amendment also clarified that no royalties are owed by us to Yungtai Hsu as of the date of the
Amendment.
A copy of the Amendment is attached hereto as Exhibit 10.1 and is incorporated by reference herein.
2